Every payer’s checklist is different. This week: Health-Related Quality of Life—how patient experience shapes coverage. MARA Rating Insight: Since 2020, drugs averaging a 2.8 HRQoL score secured reimbursement far more often than those
Datopotamab deruxtecan — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for metastatic breast cancer. Datopotamab deruxtecan has been assessed using the MARA Rating framework for its role
An overview of how different payers prioritize safety and tolerability profiles when assessing new therapies. MARA Rating Insight Since 2020, assets averaging a 3.3 Safety score cleared HTA hurdles more often than those
Ensifentrine – complimentary MARA Rating report: pricing & reimbursement risk assessment for COPD maintenance therapy. Ensifentrine, marketed as Ohtuvayre, has been reviewed under the MARA Rating system. This assessed its
Market Access Risk Assessment MARA Rating Company Obesity drives ≈ $173 billion in direct U.S. medical costs each year (2019 USD). Four next‑generation pipeline assets—Survodutide, Retatrutide, Orforglipron and the amylin/GLP‑1 co‑formulation Cagrilintide + Semaglutide (“CagriSema”)—promise weight‑loss efficacy
MARA Rating Insight Since 2020, assets averaging a 3.1 Cost-Effectiveness score sailed through HTA evaluations, while those at just 1.96 were far more likely rejected. That 1.14-point gap often determines whether payers call your
Every payer’s checklist is different. MARA Rating Insight Since 2020, assets with an average Clinical Effectiveness score of 3.1 sailed through HTA evaluations, while those averaging just 2.7 were more often rejected. That 0.4-point
Caution Flags Raised: MARA Rating (B++) Spots Access Risks in Merck’s $10B Verona Deal Merck Acquires Verona Pharma for $10B – Our B++ MARA Rating Warns of Access Hurdles Merck
Over the past five years, almost half of drug launches have fallen short of their sales forecasts due to misjudged pricing and reimbursement (P & R) risks, resulting in significant
Nipocalimab – complimentary MARA Rating report: pricing & reimbursement risk assessment for generalized myasthenia gravis. This MARA Rating® complimentary report provides a market-access risk assessment of Nipocalimab for the treatment